SAVA Stock Summary and Trading Ideas (Cassava Sciences | NASDAQ:SAVA)

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Cassava Sciences trades on the NASDAQ stock market under the symbol SAVA.

As of January 23, 2026, SAVA stock price declined to $2.20 with 661,333 million shares trading.

SAVA has a beta of 1.36, meaning it tends to be more sensitive to market movements. SAVA has a correlation of 0.07 to the broad based SPY ETF.

SAVA has a market cap of $106.28 million. This is considered a Micro Cap stock.

In the last 3 years, SAVA traded as high as $42.20 and as low as $1.15.

The top ETF exchange traded funds that SAVA belongs to (by Net Assets): VTI, VXF, VHT, IWC, AVSC.

SAVA has underperformed the market in the last year with a return of -13.0%, while the SPY ETF gained +14.2%. In the last 3 month period, SAVA fell short of the market, returning -43.7%, while SPY returned +2.9%. However, in the most recent 2 weeks SAVA has outperformed the stock market by returning +4.8%, while SPY returned -0.7%.

SAVA support price is $2.23 and resistance is $2.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SAVA shares will trade within this expected range on the day.